PSA Screening: How to Decide Whether, and When, It's Right for You

The PSA test is simple, but the decision isn't. Here's what the USPSTF and AUA/SUO guidelines say, and the questions that can help you choose.

Key takeaways

  • PSA screening is a shared decision based on your values and risk.
  • The AUA/SUO suggests a baseline PSA at 45 to 50, and earlier for higher-risk men.
  • Screening has real benefits and real harms, including overdiagnosis.
  • A high PSA is a starting point, and some medicines lower PSA.

The PSA test is a simple blood test. The decision to have one is not always so simple. PSA, or prostate-specific antigen, is a protein made by the prostate. A higher level can be a sign of prostate cancer. It can also come from an enlarged prostate, inflammation or an infection.

Prostate cancer is common. The American Cancer Society estimates that about 1 in 8 men will be diagnosed with it during their lifetime, and about 1 in 44 will die from it.1 The gap between those two numbers is the heart of the screening question. Many prostate cancers grow so slowly that they would never cause harm. Others are aggressive and are best found early.

What the major guidelines say

Two widely used U.S. recommendations agree on the most important point: screening should be a shared decision between you and your clinician, based on your values and preferences.

U.S. Preventive Services Task Force (USPSTF), 2018. For men aged 55 to 69, the decision to be screened is an individual one. It should follow a conversation about benefits and harms. The Task Force recommends against PSA-based screening for men 70 and older.2 The Task Force has posted that an update of this recommendation is in progress, so check for newer guidance.

American Urological Association and Society of Urologic Oncology (AUA/SUO), 2023, amended 2026. This urology guideline goes into more detail:34

  • PSA should be the first screening test.
  • Clinicians may offer a baseline PSA test between ages 45 and 50.
  • People at higher risk, including those of Black ancestry, those with certain inherited gene changes, and those with a strong family history of prostate cancer, should be offered screening starting at age 40 to 45.
  • From ages 50 to 69, regular screening every 2 to 4 years should be offered.
  • The time between tests can be personalized, or screening can stop, based on your preferences, age, PSA results, risk, life expectancy and general health.

Weighing benefits and harms

The main benefit of screening is finding a dangerous cancer before it spreads. The USPSTF estimated that for every 1,000 men aged 55 to 69 who are screened over about 13 years, about 1.3 deaths from prostate cancer and about 3 cases of cancer that has spread would be avoided.2

The possible harms are real too:

  • False alarms. PSA can be high for reasons other than cancer, which can lead to worry and more tests.
  • Biopsy side effects. These can include bleeding, discomfort and, less often, infection.
  • Overdiagnosis. Some cancers found through screening would never have caused symptoms or shortened a man's life.
  • Overtreatment. Surgery or radiation for a cancer that did not need it can affect bladder control and erections.

Modern care has reduced some of these harms. Many men with low-risk cancer now choose active surveillance, which means close monitoring instead of treating right away. A prostate MRI can also help decide whether a biopsy is needed and where to take samples. The AUA/SUO guideline says clinicians may use MRI before a first biopsy to improve detection of more significant cancers.5

Things that can change your PSA

One high result is a starting point, not a diagnosis. PSA often rises with an enlarged prostate, prostatitis or a urinary infection, so your clinician may repeat the test before deciding on next steps. The guideline also advises against using how fast PSA is rising, on its own, as the only reason for a biopsy or more testing.5

Some medicines lower PSA. Finasteride, which is used for an enlarged prostate, lowers PSA by about half within six months. Its label advises doubling the PSA value when comparing it with normal ranges for men not taking the drug.6 If you take finasteride or dutasteride, make sure whoever orders your PSA test knows.

How to make your decision

Before your visit, it can help to think through a few questions:

  • Did my father, brother or son have prostate cancer, especially at a younger age?
  • Is there breast, ovarian or pancreatic cancer in my family that could point to an inherited gene change?
  • How would I feel about a false alarm, or about living with a low-risk cancer that is being watched?
  • How do my age and overall health affect how much I am likely to benefit?
There is no single right answer. Some men value the chance to find cancer early. Others prefer to avoid the chain of tests a PSA result can start. Both are reasonable choices when they are informed ones.

If you decide to be screened, ask what PSA level would lead to a next step in your case, and when to repeat the test. If you decide not to be screened for now, revisit the decision if your health or family history changes.

When to see a doctor

Talk with your clinician about PSA screening if you're 45 or older, or 40 or older with Black ancestry, a strong family history or a known inherited gene change. See a doctor promptly for blood in the urine or bone pain that doesn't go away.

Sources and references

  1. American Cancer Society. Key Statistics for Prostate Cancer. Last revised January 13, 2026. View source
  2. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. View source
  3. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):46-53. View source
  4. Lin DW, Carlsson S, Filson CP, et al. Updates to early detection of prostate cancer: AUA/SUO guideline (2026). J Urol. 2026. View source
  5. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J Urol. 2023;210(1):54-63. View source
  6. PROSCAR (finasteride) tablets, US prescribing information. Revised 03/2026. View source

About the author

Dr. Justin Gould, MD

Dr. Justin Gould, MD, is a urologist with Greater Boston Urology in Milton, Massachusetts, sharing plain-language guidance on enlarged prostate (BPH), PSA screening and men's urologic health.

This article is general education for adults and is not a substitute for personal medical advice. In an emergency, call 911.

Related articles

Ready to talk about your prostate or urinary health?

Start with a private conversation with Dr. Gould at Greater Boston Urology in Milton.

Request an Appointment